Alan Santini
University of Bologna
4 Papers
Alan Santini is an academic researcher from University of Bologna. The author has contributed to research in topics: Chemistry & GSK3B. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Targeting topoisomerase II with trypthantrin derivatives: Discovery of 7-((2-(dimethylamino)ethyl)amino)indolo[2,1-b]quinazoline-6,12-dione as an antiproliferative agent and to treat cancer
Elena Catanzaro,Nibal Betari,Jose M. Arencibia,Serena Montanari,Claudia Sissi,Angela De Simone,Ivano Vassura,Alan Santini,Vincenza Andrisano,Vincenzo Tumiatti,Marco De Vivo,Dmitri V. Krysko,Marco B. L. Rocchi,Carmela Fimognari,Andrea Milelli +14 more
TL;DR: The discovery of a new topoII inhibitor, whose design was based on the structure of the natural product trypthantrin, a natural alkaloid containing a basic indoloquinazoline moiety, which represents a promising lead for developing newTopoII inhibitors as anti-cancer therapeutic agents.
31
PROTAC-Induced Glycogen Synthase Kinase 3β Degradation as a Potential Therapeutic Strategy for Alzheimer’s Disease
Melissa Guardigni,Letizia Pruccoli,Alan Santini,Angela De Simone,Matteo Bersani,Francesca Spyrakis,Flavia Frabetti,Elisa Uliassi,Vincenza Andrisano,Valle Palomo,Maria Laura Bolognesi,Andrea Tarozzi,Andrea Milelli +12 more
TL;DR: Based on proteolysis-targeting chimera (PROTAC) technology, a small set of novel GSK-3β degraders was designed and synthesized by linking two different GSK3β inhibitors, SB-216763 and tideglusib, to pomalidomide, as E3 recruiting element, through linkers of different lengths as mentioned in this paper .
20
First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
Alan Santini,Elisa Tassinari,El Poeta,Manuela Loi,Elisabetta Ciani,Stefania Trazzi,Rebecca Piccarducci,Simona Daniele,Claudia Martini,Barbara Pagliarani,Andrea Tarozzi,Matteo Bersani,Francesca Spyrakis,Daniela Danková,Christian A. Olsen,Roberto Soldati,Vincenzo Tumiatti,Serena Montanari,Angela De Simone,Andrea Milelli +19 more
TL;DR: Dual non-ATP-competitive glycogen synthase kinase 3β/histone deacetylase inhibitors as a potential therapeutic for Alzheimer's disease. The synthesized compounds are potent inhibitors of GSK-3β, HDAC2, and HDAC6 with nanomolar IC50 values. Compound 4 exhibits neuroprotective and immunomodulatory properties and has the potential to cross the blood-brain barrier.
AR-A014418-based dual Glycogen Synthase Kinase 3β/Histone Deacetylase inhibitors as potential therapeutics for Alzheimer's disease.
Alan Santini,Elisa Tassinari,Alessandra Altomare,Manuela Loi,Elisabetta Ciani,Stefania Trazzi,Rebecca Piccarducci,Simona Daniele,Claudia Martini,Barbara Pagliarani,Andrea Tarozzi,Matteo Bersani,Francesca Spyrakis,Daniela Danková,Eleonora Poeta,Simone Raimondi,Lara Davani,G. Aldini,Vincenza Andrisano,Angela De Simone,Andrea Milelli +20 more
- 01 Jun 2025